Monetta Financial Services’s Vertex Pharmaceuticals VRTX Stock Holding History

Monetta Financial Services’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-2,000	Closed	-$970K	–	60
2025 Q1	$970K	Hold	2,000	–	–	0.86%	32
2024 Q4	$805K	Hold	2,000	–	–	0.65%	45
2024 Q3	$930K	Hold	2,000	–	–	0.79%	34
2024 Q2	$937K	Hold	2,000	–	–	0.81%	35
2024 Q1	$836K	Sell	2,000 -500	-20%	-$211K	0.76%	41
2023 Q4	$1.02M	Hold	2,500	–	–	0.97%	27
2023 Q3	$869K	Hold	2,500	–	–	0.95%	30
2023 Q2	$880K	Hold	2,500	–	–	0.86%	31
2023 Q1	$788K	Hold	2,500	–	–	0.84%	30
2022 Q4	$722K	Hold	2,500	–	–	0.83%	30
2022 Q3	$724K	Sell	2,500 -1,500	-38%	-$432K	0.82%	29
2022 Q2	$1.13M	Hold	4,000	–	–	1.18%	20
2022 Q1	$1.04M	Hold	4,000	–	–	0.87%	24
2021 Q4	$878K	Buy	+4,000	New	+$778K	0.68%	30
2018 Q2	–	Sell	-7,000	Closed	-$1.14M	–	53
2018 Q1	$1.14M	Buy	+7,000	New	+$1.14M	0.61%	36

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Monetta Financial Services's VRTX Position: Q2 2025 in Review

Monetta Financial Services sold out of Vertex Pharmaceuticals (VRTX) in Q2 2025, closing a stake of 2,000 shares — an estimated $970K sold.

Monetta Financial Services first reported a position in VRTX in Q1 2018 and held it in 15 quarters. The position peaked at $1.14M in Q1 2018. 1,559 funds tracked by Wall St. Rank hold VRTX as of Q2 2025.

Monetta Financial Services reported no remaining Vertex Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Monetta Financial Services sold 2,000 Vertex Pharmaceuticals shares in Q2 2025, an estimated $970K.
Monetta Financial Services first reported a position in Vertex Pharmaceuticals in Q1 2018 and held it in 15 quarters.
Monetta Financial Services's Vertex Pharmaceuticals position peaked at $1.14M in Q1 2018.
1,559 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2025.

Based on Monetta Financial Services's 13F filing for Q2 2025, filed 8 Aug 2025.